Affymax and Takeda get special Medicare code for Omontys
16 April 2012
Takeda's GPR40 agonist for diabetes promising in Ph II trial
28 February 2012
Takeda to drop peginesatide commercialization in Japan
19 December 2011
FDA committee backs Affymax CKD drug
9 December 2011
US FDA sets PDUFA action dates for Bydureon and peginesatide
12 August 2011
Showing 1-9 of 9 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
